Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

ge total urine volume was 2,217 ml.

"Worsening renal function is an independent predictor of morbidity and mortality in heart failure. The data from this study show that administration of CD-NP in heart failure patients resulted in evidence of enhanced renal function as well as diuresis comparable to furosemide," said Joel Neutal, M.D., Associate Professor of Medicine at University of California in Irving and Medical Director of Clinical Pharmacology at Orange County Research Center. "The unique profile of CD-NP could satisfy an unmet need for the treatment of patients with acute heart failure."

"We are very pleased with the results of this Phase 1b study which support the hypothesis that the administration of CD-NP in heart failure patients results in diuresis and enhanced renal function with minimal blood pressure effects," said Peter Strumph, Chief Executive Officer of Nile. "These data, in combination with the recently announced interim Phase 2a data, give us important clinical insight into the activity and tolerability of CD-NP and confirm our belief that CD-NP can provide a novel therapeutic profile for the treatment of heart failure."

Information regarding this study is available at the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Heart Failure

Heart failure (HF) is a chronic condition in which the heart cannot effectively pump enough blood to the body's other organs. HF is a major and growing public health problem affecting 5.3 million Americans, with over 650,000 new cases diagnosed every year. The annual mortality rate for heart failure is 19%. Treatment of heart failure generates annual costs of approximately $35 billion, of which approximately $3 billion is spent on drugs and $19 billion is spent in the acute hospital setting. Heart Failu
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Recently, academic debate has been swirling around the existence ... of phenomena, including photosynthesis, the process by which organisms ... suggested that entanglement (the quantum interconnection of two or ... separated in physical space) could be occurring in the ...
... Aug. 6 Rashid Chotani , M.D., ... Programs.  In this role, Chotani will lead chemical and biological programs that ... of the Secretary of Defense, as well as civilian agencies such as ... Disease Control. , , , ...
... 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... results for the three and six months ended June 30, 2010 and reviewed the ... , The Company ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:7/9/2014)... to switch out one gene for another in a ... science fiction to reality within this decade. As with ... hope of fixing disease-causing genes in humans, for example--as ... have put one of those concerns to rest: using ... occurrence of mutations in the cells. The new results ...
(Date:7/9/2014)... LAFAYETTE, Ind. - Regulated deer hunts in Indiana state ... from decades of damage caused by overabundant populations of ... team led by Michael Jenkins, associate professor of forest ... Resources policy of organizing hunts in state parks has ... and wildflowers rendered scarce by browsing deer. , ...
(Date:7/9/2014)... from the Spanish National Cancer Research Centre (CNIO) have ... cells, also regulates cell division in stratified epitheliathose that ... cover the oesophagus or the vaginain adult organisms. According ... journal Nature Communications , this factor could also ... from stratified epithelia of the oesophagus and skin. , ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... serendipity, researchers at North Carolina State University have found ... of intestinal birth defects may also inhibit the growth ... of chemical compounds created by NC State chemist Dr. ... of particular interest to her research: a compound that ...
... Indonesia has promised to become a world leader ... committed to a 26% reduction in greenhouse gas emissions ... 14% would have to come from reducing emissions from ... and other bodies are expected to raise total emission ...
... global framework for the safe production and use of ... Australia. The South-Pacific plant has been traditionally used ... some countries. Leading world Kava experts Dr Jerome ... Teschke from Wolfgang Goethe-University, Frankfurt, Germany; and Dr Vincent ...
Cached Biology News:Compound useful for studying birth defects may also have anti-tumor properties 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 3Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 4Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 5Experts propose global guidelines for safe use of Kava and new Australian study 2
TUP1 Market Segment: Molecular Biology...
In plasmid or lambda vector. Please inquire for more details!...
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
... polyclonal to SARA ( Abpromise for ... Synthetic peptide: PVPKEMEQPV QTEEEDVELP conjugated to ... Fruit fly (Drosophila melanogaster) SARA. Conserved ... Entrez Gene ID: 9372 ...
Biology Products: